Surrogates, not sight
Today's endpoints infer tissue effect from electrical and mechanical proxies. The lesion is never observed, only estimated.
RFA & PFA • REAL-TIME LESION ASSESSMENT
Closing the recurrence gap
in cardiac ablation.
Recurrence is the main unsolved problem in atrial fibrillation ablation. AblaView®* is a catheter delivering either RFA or PFA energy that provides real-time lesion assessment (contact, stability, lesion size, durability of the ablations, gap detection, pop prediction). The system's ability to detect during ablation whether the procedure will be ineffective was confirmed at 100% specificity for durable PFA at three-month follow-up in the first-in-human study, peer-reviewed in Europace.
*The device presented is under preclinical/clinical investigation. It is not FDA approved nor CE labelled.
50 µmAXIAL RESOLUTION, 4-5X INTRACARDIAC ULTRASOUND
20 fpsLIVE DISPLAY, ACQUISITION TO SCREEN IN 50 MS
860+PRECLINICAL ABLATIONS WITH HISTOLOGY
100%SPECIFICITY, DURABLE PFA PREDICTION (FIH, EUROPACE 2025)
THE PROBLEM
Recurrence is what blindness costs.
Recurrence is the main unsolved problem in atrial fibrillation ablation. The physician creates lesions in an atrial wall that is typically 0.6 mm to 1 mm thick, guided by surrogates: contact force, power, time, impedance. None of them show the lesion itself, so gaps are found months later, when the arrhythmia returns.
Gaps appear late
Non-durable lesions and gaps in the ablation line reveal themselves after the procedure, driving redo interventions.
Thin walls, high stakes
At under a millimeter of atrial wall, the margin between an incomplete lesion and a perforation is small. Resolution matters.
THE ENABLING MECHANISM
PS-OCR: showing what electricity can't.
Polarization-Sensitive Optical Coherence Reflectometry measures tissue birefringence directly, with 50µm axial resolution. Intracardiac ultrasound is around 200µm, so PS-OCR is 4 to 5 times higher resolution. This margin matters because atrial walls are thin, typically 0.6 mm to 1 mm thick, and susceptible to perforation. A 1310 nm swept-source laser resolves individual tissue layers at the catheter tip. The physics is what makes the unique performance of AblaView® possible.
Realtime. Direct. No surrogates. The lesion durability and gap detection in realtime are the largest unsolved problem in EP ablation procedures. AblaView® is the only platform that closes it.
FOR BOTH RF AND PF
Contact quality, stability & catheter orientation. Direct optical assessment of contact quality, stability, and catheter orientation at the tip. Real-time identification of gaps during the procedure.
FOR RF ONLY
Lesion size (diameter and depth) · pop prediction. Optical readout of lesion diameter and depth during RF delivery, plus a validated steam-pop risk model, both measured directly from birefringence at the catheter tip.
FOR PF ONLY
Durability prediction. 100% specificity for durable PFA at three-month follow-up in the first-in-human study (n=10, no hemolysis, no neurovascular complications). Peer-reviewed in Europace, February 2025.
CO-AUTHORS & INVESTIGATORS
EUROPACE • 2025 • FIRST-IN-HUMAN
EUROPACE • 2025 • FIRST-IN-HUMAN
CIRCULATION • 2024 • PRECLINICAL
Peer-reviewed publication record.
Published in Europace, 2025. Preclinical PS-OCR validation in Circulation, 2024.
Co-author on the AblaView® first-in-human Europace publication, February 2025. Proctor during the first-in-human cases.
Prof. Atul Verma, MD
Director of Cardiology, McGill University Health Centre. 300+ peer-reviewed publications including NEJM. Led STAR AF II.
Co-author on the AblaView® first-in-human Europace publication, February 2025. Proctor during the first-in-human cases.
Prof. Raphaël Martins, MD, PhD
Cardiac Electrophysiologist, CHU Rennes / University of Rennes. AF mechanisms and translational ablation research.
Lead author on the AblaView® PS-OCR preclinical study published in Circulation, 2024. Directs the Preclinical Cardiovascular Lab at Sunnybrook. Specialist in preclinical evaluation of novel ablation devices.
Dr. Maria Terricabras, MD
Cardiac EP and Director, Preclinical Cardiovascular Lab, Sunnybrook / University of Toronto.
THE FILM
Three minutes inside AblaView.
The team, the platform, and the dual-energy catheter, told by the people building it.
ABLAVIEW CORPORATE FILM. 2:59. DEVICE SHOWN IS INVESTIGATIONAL.
THE MOAT
Owned physics. Paired data. Protected outputs.
The patent estate
70+ patents covering polarization-sensitive optical tissue imaging and optical-guided ablation. 9 jurisdictions. Owned outright. No licensing obligations to any third party.
70+PATENTS
9JURISDICTIONS
100%OWNED OUTRIGHT
The data asset
Every AblaView® procedure produces optical tissue measurements, and the preclinical program pairs them with histological ground truth: 860+ ablations to date. This paired corpus trains the AblaView® Clinical AI Engine that runs the live display, and it grows with every case. Good correlation has been observed between the animal and human PS-OCR output.
860+ABLATIONS WITH HISTOLOGY
20 fpsAI ENGINE, LIVE IN THE LOOP
See the evidence. Explore the system.
Dive deeper into the science and the data behind AblaView®.